Showing 1–25 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
World Health Organization
Hu Z, Lu SH, Lowrie DB, Fan XY
…l. Recently, the development of highly efficacious COVID-19 vaccines within one year accelerated the vaccine development process in human use, with the notable example of mRNA vaccines and adenovirus-vectored vaccines, and increased the public acceptance of the concept of the con…
Mario Tovar, Yamir Moreno, Joaquín Sanz
Abstract In the development of vaccines against tuberculosis (TB), a number of factors represent burdensome difficulties for the design and interpretation of randomized control trials (RCTs) of vaccine efficacy. Among them, the complexity of the transmission chain of TB allows th…
Zhou F, Zhang D
…gress has been made in research and development (R&D) of TB vaccines in the past decades, and a dozen vaccine candidates, including live attenuated mycobacterial vaccines, killed mycobacterial vaccines, adjuvanted subunit vaccines, viral vector vaccines, and messenger RNA (mRNA) …
Schön M, Heesemann E, Ebert C, Subramanyam M, Vollmer S, et al.
…and multivariable logistic regression models were used. The vaccines included targeted tuberculosis, hepatitis B, polio, diphtheria/pertussis/tetanus (DPT) and measles. Moreover predictors for perinatal health care uptake were analysed by multivariable logistic regression. Of the…
Zsofia M Hesketh, Rebecca A Clark, Rupali Limaye, Puck T Pelzer, Shaun Palmer, et al.
…ential barrier to the introduction of new tuberculosis (TB) vaccines. In the absence of TB-specific vaccine confidence surveys, analysis of general national vaccine confidence data can provide a useful proxy to determine where demand generation strategies may need to be focused a…
Tom Sumner, Rebecca A Clark, Tomos O Prys-Jones, Roel Bakker, Gavin Churchyard, et al.
…ity and mortality in people living with HIV (PLHIV). New TB vaccines may help reduce this burden. There is limited data on the response to new TB vaccines in PLHIV and how this may vary with levels of immunosuppression and anti-retroviral therapy (ART). The potential interaction …
Ochran Chetty, Cohen Chetty
… provide an overview of the clinical status of candidate TB vaccines and discuss the challenges and future development trends of novel TB vaccine research, in combination with a general overview of the Tuberculosis (TB) disease and Mycobacterium tuberculosis itself. Methods: Bibl…
Steven C. Derrick
ABSTRACT Our goal is to develop a pediatric combination vaccine to protect the vulnerable infant population against human immunodeficiency virus type 1 (HIV-1) and tuberculosis (TB) infections. The vaccine consists of an auxotroph Mycobacterium tuberculosis strain that coexpresse…
Daphne T. Lianou, Charalambia K. Michael, Efthymia Petinaki, Vasia S. Mavrogianni, George C. Fthenakis
…sheep and goat farms, respectively. The increased number of vaccines administered was associated with a higher average milk production in the respective farms. There was an association of vaccination against staphylococcal mastitis with a reduced recovery of staphylococci from th…
Quincer EM, Gobezayehu AG, Belew ML, Endalamaw LA, Tesfaye YA, et al.
…World Health Organization. We assessed the acceptability of vaccines currently administered during pregnancy [tetanus, diphtheria and COVID-19] and willingness to receive a new TB vaccine during pregnancy and/or lactation among Ethiopian women. Methods From January to February 20…
Zhuang Li, Yilu Zhao, Ling Yang, Linsheng Li, Zhaoyang Ye, et al.
Tuberculosis (TB) is a global infectious disease posing a serious threat to human health, caused by Mycobacterium tuberculosis (MTB) infection. Although vaccination is the most effective way to prevent and control TB, the existing Bacillus Calmette–Guérin (BCG) vaccine exhibits l…
Kanipe C, Boggiatto PM, Putz EJ, Palmer MV
Mycobacterium bovis ( M. bovis ) is the zoonotic bacterium responsible for bovine tuberculosis. An attenuated form of M. bovis , Bacillus Calmette-Guerin (BCG), is a modified live vaccine known to provide variable protection in cattle and other species. Protection for this vaccin…
Adetokunboh OO, Ndwandwe D, Awotiwon A, Uthman OA, Wiysonge CS
…ase-control studies that have efficacy and effectiveness of vaccines in HIV-infected and HIV-exposed children as outcomes. Web of Science, Cochrane Library, PubMed and Scopus databases were searched for articles. Efficacy of 9-valent pneumococcal conjugate vaccine (PCV9) against …
Haley M Sterle, Ellie J Putz, Mitchell V Palmer, Steven C Olsen, Paola M Boggiatto
**INTRODUCTION:** and, the causative agents of bovine brucellosis and tuberculosis respectively, are zoonotic bacterial pathogens that both contribute to major economic losses in the cattle industry and pose a human health risk worldwide. Co-infections of cattle withandhave been …
Clark RA, Weerasuriya CK, Portnoy A, Mukandavire C, Quaife M, et al.
…n tuberculosis cases and 506 thousand deaths in 2021. Novel vaccines effective in adolescents and adults could reduce this burden. M72/AS01 E and BCG-revaccination have recently completed phase IIb trials and estimates of their population-level impact are needed. We estimated the…
Yamoah P, Mensah KB, Padayachee N, Bangalee V, Oosthuizen F
The BCG vaccine, like all other vaccines, is associated with adverse events following immunization (AEFI). Reducing the incidence of AEFI is crucial in reposing confidence in BCG vaccination and reducing hesitancy associated with the vaccine. This requires safety precautions befo…
Kochhar S, Barreira D, Beattie P, Cavaleri M, Cravioto A, et al.
… or systematic approaches exist to inform developers of new vaccines of the evidence anticipated to facilitate global policy recommendations, before a vaccine candidate approaches regulatory approval at the end of pre-licensure efficacy studies. Consequently, significant delays m…
Naoto Kuroda
…tizens is necessary. If infants in Japan do not receive BCG vaccines, tuberculosis might spread. We must prevent this from happening by publicizing inadequate evidence of causality between the BCG and prevention of the COVID-19. We also need to highlight the concern that a shorta…
Speth F, Hinze CH, Andel S, Mertens T, Haas JP
Background The goal of this study was to apply the varicella zoster virus (VZV) vaccine to patients with pediatric rheumatic diseases (PRD) at risk for severe chickenpox, without interrupting their current immunosuppression, including biological agents, using an immunological-bas…
Lee S, Kim T, Seong KY, Yim SG, Lee WK, et al.
…r 8 weeks at -20 °C. In vivo vaccination tests using BCG-MN vaccines on guinea pigs exhibited no adverse reactions. Moreover, the BCG-MN vaccine demonstrated superior immune response compared to injections, suggesting that this BCG vaccine-coated MN platform has the potential as …
Machlaurin A, Pol SV, Setiawan D, van der Werf TS, Postma MJ
…s effectiveness is limited and varies by age. New candidate vaccines are currently being investigated. In response to the declining incidence of TB, practices relating to BCG vaccination have changed in various countries in recent years. A valid cost-effectiveness study is theref…
Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, et al.
Background A vaccine that prevents pulmonary tuberculosis in adults is needed to halt transmission in endemic regions. This trial aimed to assess the safety and immunogenicity of three administrations at varying doses of antigen and adjuvant of an investigational vaccine (ID93 + …
Hope JC, Khalid H, Thom ML, Howard CJ, Shaw DJ
Mycobacterium bovis , the causative agent of bovine tuberculosis (bTB), is a globally prevalent pathogen with significant animal welfare, economic and public health impacts. In the UK, the control of bTB relies on detection via tuberculin skin tests with ancillary interferon gamm…
Augustinas Stasiūnas, Jurgita Stasiūnienė, Enrika Didžiulienė
…-rapid seroconversion. Understanding this BCG and influenza vaccines interaction is crucial for healthcare providers to differentiate between benign post-vaccination reactions and those that may require further clinical evaluation.